<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id><journal-title-group><journal-title>BMC Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1471-230X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23602047</article-id><article-id pub-id-type="pmc">3651308</article-id><article-id pub-id-type="publisher-id">1471-230X-13-68</article-id><article-id pub-id-type="doi">10.1186/1471-230X-13-68</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Everitt</surname><given-names>Hazel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hae1@soton.ac.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Moss-Morris</surname><given-names>Rona</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Rona.moss-morris@kcl.ac.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Sibelli</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>a.sibelli@ucl.ac.uk</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Tapp</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>tapp15@hotmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Coleman</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Nicholas.Coleman@suht.swest.nhs.uk</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Yardley</surname><given-names>Lucy</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>L.Yardley@soton.ac.uk</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Smith</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>P.W.Smith@soton.ac.uk</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Little</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>P.Little@soton.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Primary Medical Care, School of Medicine, University of Southampton, Southampton, SO17 1BJ, UK</aff><aff id="I2"><label>2</label>Health Psychology Section, Psychology Department, |Institute of Psychiatry KCL, London Bridge, London, SE1 9RT, UK</aff><aff id="I3"><label>3</label>Centre for Behavioural Medicine, Department of Practice and Policy, School of Pharmacy, University College London, London, WC1N 1AX, UK</aff><aff id="I4"><label>4</label>Camborne Physiotherapy Outpatients Department, Camborne Redruth, Community Hospital, Barncoose Terrace, Redruth, England, Cornwall, TR15 3ER, UK</aff><aff id="I5"><label>5</label>Southampton University Hospital Trust, Southampton, UK</aff><aff id="I6"><label>6</label>School of Psychology, University of Southampton, Southampton, SO17 1BJ, UK</aff><aff id="I7"><label>7</label>Southampton Statistical Sciences Research Institute, University of Southampton, Southampton, SO17 1BJ, UK</aff><aff id="I8"><label>8</label>Primary Medical Care, School of Medicine, University of Southampton, Southampton, SO17 1BJ, UK</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>4</month><year>2013</year></pub-date><volume>13</volume><fpage>68</fpage><lpage>68</lpage><history><date date-type="received"><day>14</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>8</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2013 Everitt et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Everitt et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-230X/13/68"/><abstract><sec><title>Background</title><p>Many patients with IBS suffer on-going symptoms. The evidence base is poor for IBS drugs but they are widely prescribed and advised in Guidelines. Cognitive Behavioural Therapy (CBT) can be helpful, but availability is poor in the NHS. We developed a web-based CBT self-management programme (Regul8) in partnership with patients and trialled it and common IBS medications in an exploratory factorial RCT to test trial procedures and provide information for a larger trial.</p></sec><sec><title>Methods</title><p>Patients, 16 to 60&#x000a0;years, with IBS symptoms fulfilling Rome III criteria were recruited via GP practices and randomised to over-encapsulated mebeverine, methylcellulose or placebo for 6&#x000a0;weeks and to 1 of 3 website conditions: Regul8 with a nurse telephone session and email support, Regul8 with minimal email support, or no website.</p></sec><sec><title>Results</title><p>135 patients recruited from 26 GP practices. Mean IBS SSS score 241.9 (sd 87.7), IBS-QOL 64 (sd 20) at baseline. 91% follow-up at 12&#x000a0;weeks. Mean IBS SSS decreased by 35 points from baseline to 12&#x000a0;weeks. There was no significant difference in IBS SSS or IBS-QOL score between medication or website groups at 12&#x000a0;weeks, or in medication groups at 6&#x000a0;weeks, or IBS-QOL in website groups at 6&#x000a0;weeks. However, IBS SSS at 6&#x000a0;weeks was lower in the No website group than the website groups (IBS SSS no website =162.8 (95% CI 137.4-188.3), website 197.0 (172.4 - 221.7), Website + telephone support 208.0 (183.1-233.0) p&#x02009;=&#x02009;0.037).</p><p>Enablement and Subjects Global Assessment of relief (SGA) were significantly improved in the Regul8 groups compared to the non-website group at 12&#x000a0;weeks (Enablement =&#x02009;0 in 56.8% of No website group, 18.4% website, 10.5% Website + support, p&#x02009;=&#x02009;0.001) (SGA; 32.4% responders in No website group, 45.7% website group, 63.2% website + support group, p&#x02009;=&#x02009;0.035).</p></sec><sec><title>Conclusions</title><p>This exploratory study demonstrates feasibility and high follow-up rates and provides information for a larger trial. Primary outcomes (IBS SS and IBS QOL) did not reach significance at 6 or 12&#x000a0;weeks, apart from IBS SSS being lower in the no-website group at 6&#x000a0;weeks - this disappeared by 12&#x000a0;weeks. Improved Enablement suggests patients with access to the Regul8 website felt better able to cope with their symptoms than the non-website group. Improved SGA score in the Regul8 groups may indicate some overall improvement not captured on other measures.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov Identifier (NCT number): <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00934973?term=IBS+and+CBT&#x00026;rank=8">NCT00934973</ext-link>.</p></sec></abstract><kwd-group><kwd>Irritable bowel syndrome</kwd><kwd>Cognitive behavioural therapy</kwd><kwd>Web-based intervention</kwd><kwd>Self-management</kwd><kwd>Primary care</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder that affects 10 &#x02013; 22% of the UK population and costs the National Health Service (NHS) over 200 million pounds a year [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Abdominal pain, bloating and altered bowel habit affect quality of life, social functioning and time off work [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Treatment relies on a positive diagnosis, reassurance, lifestyle advice, and drug and psychological therapies [<xref ref-type="bibr" rid="B5">5</xref>]. However, many patients suffer on-going symptoms.</p><p>Bulking agents and antispasmodics are the most commonly prescribed medications in the UK and Europe. IBS Guidelines [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>] and a Cochrane review [<xref ref-type="bibr" rid="B6">6</xref>] have highlighted the lack of evidence for the current drug management but still recommend them as first line management in primary care. Most studies of anti-spasmodics and bulking agents for IBS were undertaken a long time ago, are of poor quality, with small numbers, in a secondary care setting. Thus, neither doctors nor patients have good evidence to inform prescribing decisions in primary care which is where most patients are managed. However, IBS drugs are recommended in the guidelines [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>] and very widely used. In 2005, NHS costs were nearly &#x000a3;10 million for mebeverine and over &#x000a3;8 million for fibre-based bulking agents (Prescription Cost Analysis figures). Trials of mebeverine and a fibre-based bulking agent would help to provide evidence to inform prescribing decisions in IBS.</p><p>Psychological therapies, such as face to face Cognitive Behavioural Therapy (CBT) have been shown to be helpful for IBS (symptoms and global wellbeing) particularly in the short term, though there is less evidence in the longer term [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. NICE Guidelines [<xref ref-type="bibr" rid="B5">5</xref>] state that there is good evidence to show a significant global improvement in IBS symptoms with CBT compared to no treatment. NICE recommended psychological therapies for patients with resistant IBS that has not responded to other measures after 12&#x000a0;months. However, availability is very limited, CBT in this format has not been proven to be cost effective [<xref ref-type="bibr" rid="B12">12</xref>] and there are problems with high drop-out rates [<xref ref-type="bibr" rid="B12">12</xref>]. Web-based CBT has been shown to be helpful for other conditions, e.g. depression [<xref ref-type="bibr" rid="B13">13</xref>] and tinnitus [<xref ref-type="bibr" rid="B14">14</xref>], insomnia [<xref ref-type="bibr" rid="B15">15</xref>] and NICE has recommended the use of web-based CBT for depression, panic and phobia in Primary Care [<xref ref-type="bibr" rid="B16">16</xref>]. Thus, web-based CBT could be an efficient, cost effective way of providing help to those with IBS. Despite extensive literature searching before the start of this study, we found no published evaluations of web-based CBT programmes for IBS. A mindfulness study and a small CBT study have since been published [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Development and testing of a web-based CBT programme for IBS has the potential to make CBT more widely available for IBS with minimally increased costs. The increasing availability of the internet makes this a good medium to provide easily accessible patient information and self-management programmes.</p><sec><title>Aims</title><p>To undertake an exploratory factorial RCT to assess the effectiveness of the prescribed medications in UK general practice for IBS: mebeverine (an anti-spasmodic) and methylcellulose (bulking-agent) against placebo, and Regul8, a CBT self-management website for IBS developed specifically for this study.</p></sec></sec><sec sec-type="methods"><title>Methods</title><p>The study protocol has been published on BMC Gastroenterology providing a fuller description of the method [<xref ref-type="bibr" rid="B19">19</xref>]. Full Ethical Approval was granted by Southampton A Ethics committee: Reference number: 09/H0502/101.</p><p>Patients with IBS were identified by searching GPs&#x02019; lists and by opportunistic recruitment of presenting patients. Potential participants were sent a letter inviting them to take part. GP practices in urban and rural settings and differing socio-demographic characteristics were included. Informed written consent was obtained from all participants.</p><sec><title>Inclusion criteria</title><p>Patients aged 16 to 60&#x000a0;years with symptoms of IBS that fulfil Rome III criteria (maximum 60&#x000a0;years as NICE guidelines advise that a new change in bowel habit over 60&#x000a0;years should have further investigations [<xref ref-type="bibr" rid="B5">5</xref>]) Potentially eligible participants had screening bloods (full blood count (FBC), transglutaminase antibodies (TTG) and a C-Reactive protein (CRP) to exclude alternative diagnoses, i.e. anaemia and Coeliacs disease).</p></sec></sec><sec><title>Exclusion criteria</title><p>Atypical symptoms &#x02013; (unexplained weight loss or rectal bleeding), diagnosis of inflammatory bowel disease, coeliac disease or peptic ulcer disease, pregnant or breast feeding, currently taking or allergy to mebeverine or methylcellulose.</p><sec><title>Regul8 self-management web-based programme</title><p>We developed a web-based CBT self-management programme for IBS based on a paper-based manual [<xref ref-type="bibr" rid="B20">20</xref>] originally developed and tested by one of our team in a RCT in primary care (RMM) [<xref ref-type="bibr" rid="B20">20</xref>]. LifeGuide software was used to develop the website [<xref ref-type="bibr" rid="B21">21</xref>]. As each web-based module was developed, &#x02018;Think Aloud&#x02019; [<xref ref-type="bibr" rid="B22">22</xref>] interviews were undertaken with four patients with IBS to ensure that the website was relevant, understandable, navigable and user friendly. The feedback was used to modify the site during development. The intervention consists of 8 sessions for participants to work through over 6&#x000a0;weeks (see Table&#x000a0;<xref ref-type="table" rid="T1">1</xref> for an overview of each session) and includes interactive components such as: development of a personal model, symptom diaries, goal sheets and thought records. Interactive components help users to remember advice, reflect and provide a &#x0201c;substitute&#x0201d; for the therapist [<xref ref-type="bibr" rid="B23">23</xref>]. Tailoring feedback to users' symptoms, allows them to focus on personally relevant aspects of the programme. Early in each session participants review key points from the previous session and review their homework, thereby reinforcing previous learning.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Summary of the Regul8 web-based self-management sessions</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/></colgroup><tbody valign="top"><tr><td rowspan="3" align="left" valign="top"><bold>Session 1:</bold> Understanding your IBS<hr/></td><td align="left" valign="bottom">Rationale for self-management which includes the following explanations:<hr/></td></tr><tr><td align="left" valign="bottom">1. Possible causes of IBS and illustrative physiology of the digestive system together with the functional changes that occur in the gut as a result of IBS.<hr/></td></tr><tr><td align="left" valign="bottom">2. How the autonomic nervous system (&#x0201c;fight-or-flight&#x0201d; stress system) may interact with the enteric nervous system.<hr/></td></tr><tr><td rowspan="3" align="left" valign="top"><bold>Session 2:</bold> Assessing your symptoms<hr/></td><td align="left" valign="bottom">Self-assessment of the interaction between thoughts, feeling and behaviours and how these can impact on stress levels and gut symptoms.<hr/></td></tr><tr><td align="left" valign="bottom">Development of a personal model of IBS which incorporates these elements.<hr/></td></tr><tr><td align="left" valign="bottom">Homework: Daily diaries of the severity and experience of IBS symptoms in conjunction with stress levels and eating routines/behaviours.<hr/></td></tr><tr><td rowspan="4" align="left" valign="top"><bold>Session 3:</bold> Managing Symptoms and Eating<hr/></td><td align="left" valign="bottom">Review of the symptom diary.<hr/></td></tr><tr><td align="left" valign="bottom">Behavioural management of the symptoms of diarrhoea and constipation, and common myths in this area are discussed. Goal setting is explained.<hr/></td></tr><tr><td align="left" valign="bottom">The importance of healthy, regular eating and not being overly focused on elimination is covered.<hr/></td></tr><tr><td align="left" valign="bottom">Homework: Goal setting for managing symptoms and regular/healthy eating. Goal setting, monitoring and evaluation continue weekly throughout the programme.<hr/></td></tr><tr><td rowspan="3" align="left" valign="top"><bold>Session 4:</bold> Exercise and Activity<hr/></td><td align="left" valign="bottom">Importance of exercise in symptom management is covered.<hr/></td></tr><tr><td align="left" valign="bottom">Identifying activity patterns such as resting too much in response to symptoms or an all-or-nothing style of activity is addressed.<hr/></td></tr><tr><td align="left" valign="bottom">Homework: Goal setting for regular exercise and managing unhelpful activity patterns if relevant.<hr/></td></tr><tr><td rowspan="3" align="left" valign="top"><bold>Session 5:</bold> Identifying your thought patterns<hr/></td><td align="left" valign="bottom">Identifying unhelpful thought (negative automatic thoughts) in relation to high personal expectations and IBS symptoms is introduced.<hr/></td></tr><tr><td align="left" valign="bottom">Link between these thoughts, feelings, behaviours and symptoms is reinforced.<hr/></td></tr><tr><td align="left" valign="bottom">Homework: Goal setting plus daily thought records of unhelpful thoughts related to personal expectations and patterns of over activity.<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Session 6:</bold> Alternative thoughts<hr/></td><td align="left" valign="bottom">The steps for coming up with alternatives to unhelpful thoughts are covered together with personal examples.<hr/></td></tr><tr><td align="left" valign="bottom">Homework: Goal setting plus daily thought records including coming up with realistic alternative thoughts.<hr/></td></tr><tr><td rowspan="3" align="left" valign="top"><bold>Session 7:</bold> Managing Stress and Sleep<hr/></td><td align="left" valign="bottom">Basic stress management and sleep hygiene are discussed.<hr/></td></tr><tr><td align="left" valign="bottom">Diaphragmatic breathing, progressive muscle relaxation and guided imagery relaxation are presented in video and audio formats.<hr/></td></tr><tr><td align="left" valign="bottom">Homework: Goal setting for stress management, relaxation techniques and good sleep habits.<hr/></td></tr><tr><td align="left"><bold>Session 8:</bold> Managing flare-ups and the future</td><td align="left">The probability of flare-ups is discussed and patients are encouraged to develop achievable, long term goals and to continue to employ the skills they have learnt throughout the manual to manage flare-ups and ongoing symptoms.</td></tr></tbody></table></table-wrap></sec><sec><title>Intervention</title><p>Patients were randomised to: mebeverine (135&#x000a0;mg three times a day), methylcellulose (3 tablets twice a day), or a placebo tablets for 6&#x000a0;weeks. To ensure double blinding, all participants took three over-encapsulated identical tablets in the morning, one at lunchtime and three at dinnertime.</p><p>They were also randomised to 1 of 3 website conditions: access to Regul8 with a 30&#x000a0;minute nurse telephone session (to encourage engagement with the CBT programme) and email support on request; the website with minimal support (i.e. technical email support on request), or no website, thus creating 9 groups.</p><p>Baseline characteristics were collected by on-line questionnaire including: gender, age, length of symptoms, deprivation score, IBS type and educational level. All patients received a telephone call in the first week to check they had no problems with the medication or paperwork. Those not randomised to website access received standard patient information and were offered website access at the end of the trial.</p></sec><sec><title>Telephone session</title><p>The telephone session in the &#x02018;website with telephone support&#x02019; group was scheduled after patients completed session 2 where they develop their own personal model of how their thoughts, feelings and behaviours might be contributing to their IBS symptoms. The purpose of the session was for the patients to clarify their model, to help extend their model and to motivate patients to continue using the website. To ensure treatment fidelity one practice nurse delivered all the telephone sessions. Prior to undertaking the sessions, the nurse received six training sessions including a basic introduction to CBT techniques. All telephone sessions were audio-taped. RMM regularly listened to the tapes and provided fortnightly supervision to the nurse during the trial.</p></sec><sec><title>Randomisation</title><p>A randomisation list was computer generated independently of the research team. Participants were block randomised in blocks of 9 and stratified by type of IBS (i.e. diarrhoea predominant, constipation predominant, alternating-pattern) as there might be a different response to the medications between these sub-groups.</p></sec><sec><title>Outcome measures</title><sec><title>Primary outcome measures</title><p>Change in the Irritable Bowel Symptom Severity Scale (IBS SSS score) [<xref ref-type="bibr" rid="B24">24</xref>] and IBS Quality of Life Questionnaire (IBS-QOL) [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>] from baseline to 12&#x000a0;weeks. Primary outcome data were collected at baseline and 6 and 12&#x000a0;weeks post randomisation.</p><p>The rationale for including two primary outcome measures is that IBS is a chronic relapsing/remitting condition. It is both the severity of the symptoms in themselves and the sufferer&#x02019;s ability to manage and live with the symptoms and their resultant quality of life that are important. CBT may have a greater effect on peoples&#x02019; ability to live with and manage their symptoms than on the severity of the symptoms themselves so it is particularly important to include quality of life as a main outcome in studies such as this.</p></sec><sec><title>Secondary outcome measures</title><p>Patient Enablement Questionnaire [<xref ref-type="bibr" rid="B27">27</xref>] (measured at 6 and 12&#x000a0;weeks), Subjects Global Assessment of Relief (SGA of Relief) [<xref ref-type="bibr" rid="B28">28</xref>] (measured at 12&#x000a0;weeks), Hospital Anxiety and Depression Scale (HADS) [<xref ref-type="bibr" rid="B29">29</xref>] (measured at baseline, 6 and 12&#x000a0;weeks). In SGA of relief participants rate their relief from IBS symptoms on a scale of 1 to 5 ranging from "completely relieved" to "worse". Scores are dichotomized; patients scoring from 1&#x02013;3 are considered responders, those 4&#x02013;5, non-responders as has been undertaken in previous studies [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Patient enablement questionnaire [<xref ref-type="bibr" rid="B27">27</xref>] assesses participants&#x02019; ability to cope with their illness and life based on 6 questions scored 0 to 2.</p><p>Qualitative interviews were undertaken with 30 participants regarding their experience of participating in the trial, the acceptability of the trial procedures, including the medication taking and perceptions of the web-based self-management programme. These results will be presented in a separate paper.</p><p><italic>Sample size:</italic> The aim of this pilot was to have sufficient numbers to assess both the feasibility of trial procedures and to provide an estimate of the likely differences between the groups. The previous trial of CBT in primary care [<xref ref-type="bibr" rid="B8">8</xref>] demonstrated a 68 point reduction in symptoms score (a standardised effect size of more than 0.8). Assuming an initial mean symptom score of 250 (SD 80) in all groups, 35 patients were required in each group to detect a difference in score of 53 points (a moderate standardised effects size of 0.66) between the treatment groups (mebeverine, methylcellulose and placebo) or the three website groups (none, minimal support, telephone) for 80% power and 95% confidence. Allowing for drop outs at 20%, we estimated 130 participants would be needed. 135 patients facilitated similar numbers in each of the 9 randomisation groups. Given the different modes of action of the interventions we assumed no interaction between the website and medication interventions.</p></sec></sec><sec><title>Statistical analyses</title><p>The statistical analyses were performed with SPSS. Data screening showed that the assumptions of normality were met for the distributions of all the variables except for HADS depression subscale and Enablement scale. Both sub-scales were divided in groups according to their distribution and then ordinal regressions were conducted for analysis. All treatment analyses were intention to treat and considered exploratory. Missing data was handled by the &#x02018;last observation carried forward&#x02019; method.</p><p>We conducted ANCOVA for the IBS SSS scores, the IBS-QOL scores, and the HADS anxiety sub-scale at 6 and 12&#x000a0;week follow-ups to control for baseline and for potentially confounding variables. We conducted a binary regression for the SGA dichotomous score (Responders/Non responders) at 12&#x000a0;week follow-up.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Recruitment</title><p>5715 invitation letters were sent from 26 GP practices to patients on their practice lists with a diagnosis code for IBS. 431 positive replies were received, 265 potential participants completed on-line screening and167 were eligible but 4 of these were excluded after screening blood tests. 135 participants entered the trial (see Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>: CONSORT Diagram).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>CONSORT diagram.</p></caption><graphic xlink:href="1471-230X-13-68-1"/></fig></sec><sec><title>Decline to participate data</title><p>673 patients returned a reply slip declining to take part in the study. Reported reasons for declining: 127 said they did not have time in their daily schedule, 162 did not wish to take medications, 33 were already taking Mebeverine or Methylcelluose and did not wish to stop them, 53 did not wish to take part in the self-management programme, 366 said IBS symptoms had improved and that they did not need additional help, 50 said they did not know they had an IBS diagnosis, and 15 did not have computer access. Patients could choose more than one option for declining.</p></sec><sec><title>Follow&#x02013;up</title><p>A total of 126/135 participants (93%) completed the six week-follow up and 123/135 (91%) completed the twelve week follow-up.</p></sec><sec><title>Compliance with Regul8</title><p>91 participants were allocated to either website alone or website with support. The number of sessions undertaken by participants ranged from 0 to 8 (all sessions), with 7 participants completing no sessions and 21 completing 8 sessions, the median was 4 sessions. Compliance was defined as complying with 4 or more sessions. Overall, 51/91 (56%) complied with the self-management programme. 23/45 (51%) participants randomised to website only and 28/46 (61%) randomised to the website plus telephone support complied.</p></sec><sec><title>Compliance with drugs</title><p>Compliance with medicine taking overall was 80% based collection of medication boxes at the end of the trial (data available for 91/135). Only 13/135 stopped taking the medications (11%). We had expected some drop out from medication taking considering the requirement to take 7 over-encapsulated tablets daily for six weeks. 7/13 of these participants stated they stopped the medication because their IBS symptoms worsened. 6/13 did not give a reason.</p></sec><sec><title>Telephone sessions</title><p>40/46 (87%) participants in the website plus support group received the support telephone session. Of the 6 participants who did not receive the sessions, 3 declined the invitation but continued working on the self-management programme, 1 was not contactable but continued working on the website, and 2 withdrew from the trial after randomisation.</p></sec><sec><title>Stratification by IBS type</title><p>This pilot trial showed that it was feasible to stratify participants by IBS type (Constipation, Diarrhoea or Mix pattern IBS) and that trial procedures worked well for this. No statistical analysis by stratification was planned for the pilot to as it was not powered for this. However, a stated aim in the protocol was to examine the data for any worsening of symptoms in the Diarrhoea predominant IBS strata that received methylcellulose. There was no evidence of increased dropouts or reported adverse events, so there is no indication that this group should be excluded from a larger trial.</p></sec><sec><title>Baseline patient characteristics (Tables&#x000a0;<xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>)</title><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Randomised participants by website group</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left" valign="top"><bold>Variable</bold></th><th align="center" valign="bottom"><bold>Website only</bold><hr/></th><th align="center" valign="bottom"><bold>Website with support</bold><hr/></th><th align="center" valign="bottom"><bold>No website</bold><hr/></th><th rowspan="2" align="center" valign="top"><bold>Test</bold></th></tr><tr><th align="center"><bold>N&#x02009;=&#x02009;45</bold></th><th align="center"><bold>N&#x02009;=&#x02009;45</bold></th><th align="center"><bold>N&#x02009;=&#x02009;45</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><italic>Age (years), mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">45.76 (9.21)<hr/></td><td align="center" valign="bottom">45.13 (10.13)<hr/></td><td align="center" valign="bottom">42.18 (11.48)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;1.524, p&#x02009;=&#x02009;0.222<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Length of symptoms (years), mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">10.51 (8.19)<hr/></td><td align="center" valign="bottom">12.87 (9.47)<hr/></td><td align="center" valign="bottom">9.00 (8.14)<hr/></td><td align="center" valign="bottom">KW, ap&#x02009;=&#x02009;0.129<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Median (IQR)</italic></bold><hr/></td><td align="center" valign="bottom">10.00 (12.00)<hr/></td><td align="center" valign="bottom">12.00 (15.00)<hr/></td><td align="center" valign="bottom">7.50 (8.75)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-SSS total, mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">237.33 (85.36)<hr/></td><td align="center" valign="bottom">237.30 (100.78)<hr/></td><td align="center" valign="bottom">251.36 (75.92)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;0.377, p&#x02009;=&#x02009;0.687<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-QOL score, mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">67.32 (17.89)<hr/></td><td align="center" valign="bottom">60.00 (3.13)<hr/></td><td align="center" valign="bottom">64.86 (19.39)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;1.65, p&#x02009;=&#x02009;0.20<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for anxiety, mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">8.73 (3.40)<hr/></td><td align="center" valign="bottom">9.46 (3.91)<hr/></td><td align="center" valign="bottom">10.00 (4.12)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;1.23, p&#x02009;=&#x02009;0.30<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for depression, mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">4.20 (2.87)<hr/></td><td align="center" valign="bottom">5.26 (3.68)<hr/></td><td align="center" valign="bottom">5.32 (3.56)<hr/></td><td align="center" valign="bottom">KW, ap&#x02009;=&#x02009;0.263<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Median (IQR)</italic></bold><hr/></td><td align="center" valign="bottom">4 (4)<hr/></td><td align="center" valign="bottom">5 (6)<hr/></td><td align="center" valign="bottom">5 (5)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Deprivation score, mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">12.27 (9.07)<hr/></td><td align="center" valign="bottom">8.65 (5.54)<hr/></td><td align="center" valign="bottom">12.81 (9.40)<hr/></td><td align="center" valign="bottom">KW, ap&#x02009;=&#x02009;0.026*<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Median (IQR)</italic></bold><hr/></td><td align="center" valign="bottom">10.06 (9.79)<hr/></td><td align="center" valign="bottom">6.57 (7.63)<hr/></td><td align="center" valign="bottom">9.79 (9.21)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Gender n (%)</italic></bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Male</italic></bold><hr/></td><td align="center" valign="bottom">14 (46.7)<hr/></td><td align="center" valign="bottom">12 (40.0)<hr/></td><td align="center" valign="bottom">4 (13.3)<hr/></td><td align="center" valign="bottom">X<sup>2</sup>(2)&#x02009;=&#x02009;6.844, p&#x02009;=&#x02009;0.034*<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Female</italic></bold><hr/></td><td align="center" valign="bottom">31(29.5)<hr/></td><td align="center" valign="bottom">34 (32.4)<hr/></td><td align="center" valign="bottom">40 (38.1)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Type of IBS n (%)</italic></bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<sup>2</sup>(4)&#x02009;=&#x02009;0.70, p&#x02009;=&#x02009;0.953<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Constipation</italic></bold><hr/></td><td align="center" valign="bottom">5 (38.5)<hr/></td><td align="center" valign="bottom">5 (38.5)<hr/></td><td align="center" valign="bottom">3 (23.1)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Diarrhoea</italic></bold><hr/></td><td align="center" valign="bottom">14 (34.1)<hr/></td><td align="center" valign="bottom">13 (31.7)<hr/></td><td align="center" valign="bottom">14 (34.1)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Mixed</italic></bold><hr/></td><td align="center" valign="bottom">26 (32.1)<hr/></td><td align="center" valign="bottom">28 (34.6)<hr/></td><td align="center" valign="bottom">27 (33.3)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Severity IBS on IBS SSS n (%)</italic></bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Mild</italic></bold><hr/></td><td align="center" valign="bottom">10 (33.3)<hr/></td><td align="center" valign="bottom">12 (40.0)<hr/></td><td align="center" valign="bottom">8 (26.7)<hr/></td><td align="center" valign="bottom">X<sup>2</sup>(4)&#x02009;=&#x02009;1.37, p&#x02009;=&#x02009;0.85<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Moderate</italic></bold><hr/></td><td align="center" valign="bottom">24 (32.4)<hr/></td><td align="center" valign="bottom">23 (31.1)<hr/></td><td align="center" valign="bottom">27 (36.5)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Severe</italic></bold><hr/></td><td align="center" valign="bottom">11 (35.5)<hr/></td><td align="center" valign="bottom">11 (35.5)<hr/></td><td align="center" valign="bottom">9 (29.0)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Education n (%)</italic></bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<sup>2</sup>(10)&#x02009;=&#x02009;3.65, p&#x02009;=&#x02009;0.97<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>No formal</italic></bold><hr/></td><td align="center" valign="bottom">2 (25.0)<hr/></td><td align="center" valign="bottom">4 (50.0)<hr/></td><td align="center" valign="bottom">2 (25.0)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>GSCE/O</italic></bold><hr/></td><td align="center" valign="bottom">11 (31.4)<hr/></td><td align="center" valign="bottom">11 (31.4)<hr/></td><td align="center" valign="bottom">13 (37.1)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>A level</italic></bold><hr/></td><td align="center" valign="bottom">11 (32.4)<hr/></td><td align="center" valign="bottom">10 (29.4)<hr/></td><td align="center" valign="bottom">13 (38.2)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Degree</italic></bold><hr/></td><td align="center" valign="bottom">12 (38.7)<hr/></td><td align="center" valign="bottom">10 (32.3)<hr/></td><td align="center" valign="bottom">9 (29.0)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Postgraduate</italic></bold><hr/></td><td align="center" valign="bottom">5 (33.3)<hr/></td><td align="center" valign="bottom">7 (46.7)<hr/></td><td align="center" valign="bottom">3 (20.0)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">&#x02003;&#x000a0;<bold><italic>Other</italic></bold></td><td align="center">4 (33.3)</td><td align="center">4 (33.3)</td><td align="center">4 (33.3)</td><td align="center">&#x000a0;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Randomised participants by medicine group</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left" valign="top"><bold>Variable</bold></th><th align="center" valign="bottom"><bold>Mebeverine</bold><hr/></th><th align="center" valign="bottom"><bold>Methylcellulose</bold><hr/></th><th align="center" valign="bottom"><bold>Placebo</bold><hr/></th><th rowspan="2" align="center" valign="top"><bold>Test</bold></th></tr><tr><th align="center"><bold>N&#x02009;=&#x02009;44</bold></th><th align="center"><bold>N&#x02009;=&#x02009;46</bold></th><th align="center"><bold>N&#x02009;=&#x02009;46</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><italic>Age (years), mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">45.44 (7.73)<hr/></td><td align="center" valign="bottom">43.52 (12.22)<hr/></td><td align="center" valign="bottom">44.24 (10.57)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;0.385, p&#x02009;=&#x02009;0.68<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Length of symptoms(years) - mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">11.20 (8.94)<hr/></td><td align="center" valign="bottom">10.30 (9.05)<hr/></td><td align="center" valign="bottom">10.91 (8.34)<hr/></td><td align="center" valign="bottom">KW, ap&#x02009;=&#x02009;0.783<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Median (IQR)<hr/></td><td align="center" valign="bottom">10.00 (11.00)<hr/></td><td align="center" valign="bottom">8.50 (12.00)<hr/></td><td align="center" valign="bottom">10.00 (11.00)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-SSS total score - mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">270.02 (77.27)<hr/></td><td align="center" valign="bottom">233.15 (89.19)<hr/></td><td align="center" valign="bottom">224.35 (90.79)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;3.483, p&#x02009;=&#x02009;0.034*<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-QOL score - mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">59.58 (20.60)<hr/></td><td align="center" valign="bottom">65.70 (18.64)<hr/></td><td align="center" valign="bottom">66.51 (19.49)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;1.65, p&#x02009;=&#x02009;0.20<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for anxiety- mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">9.23 (4.02)<hr/></td><td align="center" valign="bottom">9.57 (4.19)<hr/></td><td align="center" valign="bottom">9.37 (3.30)<hr/></td><td align="center" valign="bottom">F(2,132)&#x02009;=&#x02009;0.84, p&#x02009;=&#x02009;0.92<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for depression - mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">5.76 (3.75)<hr/></td><td align="center" valign="bottom">4.22 (4)<hr/></td><td align="center" valign="bottom">4.93 (3.25)<hr/></td><td align="center" valign="bottom">KW, ap&#x02009;=&#x02009;0.109<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Median (IQR)</italic></bold><hr/></td><td align="center" valign="bottom">6.00 (6.00)<hr/></td><td align="center" valign="bottom">3.00 (4.00)<hr/></td><td align="center" valign="bottom">4.00 (6.00)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Deprivation score, mean (SD)</italic></bold><hr/></td><td align="center" valign="bottom">12.19 (8.57)<hr/></td><td align="center" valign="bottom">11.38 (8.87)<hr/></td><td align="center" valign="bottom">10.12 (7.52)<hr/></td><td align="center" valign="bottom">KW, ap&#x02009;=&#x02009;0.499<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Median (IQR)</italic></bold><hr/></td><td align="center" valign="bottom">10.06 (9.71)<hr/></td><td align="center" valign="bottom">8.00 (9.56)<hr/></td><td align="center" valign="bottom">8.25 (7.26)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Gender - n (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Male</italic></bold><hr/></td><td align="center" valign="bottom">12 (40.0)<hr/></td><td align="center" valign="bottom">9 (30.0)<hr/></td><td align="center" valign="bottom">9 (30.0)<hr/></td><td align="center" valign="bottom">X2(2)&#x02009;=&#x02009;1.18, p&#x02009;=&#x02009;0.57<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Female</italic></bold><hr/></td><td align="center" valign="bottom">31 (29.5)<hr/></td><td align="center" valign="bottom">37 (35.2)<hr/></td><td align="center" valign="bottom">37 (35.2)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Type of IBS - n (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Constipation</italic></bold><hr/></td><td align="center" valign="bottom">5 (38.5)<hr/></td><td align="center" valign="bottom">3 (23.1)<hr/></td><td align="center" valign="bottom">5 (38.5)<hr/></td><td align="center" valign="bottom">X2(4)&#x02009;=&#x02009;0.893, p&#x02009;=&#x02009;0.932<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Diarrhoea</italic></bold><hr/></td><td align="center" valign="bottom">13 (31.7)<hr/></td><td align="center" valign="bottom">15 (36.6)<hr/></td><td align="center" valign="bottom">13 (31.7)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Mixed</italic></bold><hr/></td><td align="center" valign="bottom">25 (30.9)<hr/></td><td align="center" valign="bottom">28 (34.6)<hr/></td><td align="center" valign="bottom">28 (34.6)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Severity IBSon IBS SSS n (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X2(4)&#x02009;=&#x02009;11.48, p&#x02009;=&#x02009;0.021*<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Mild</italic></bold><hr/></td><td align="center" valign="bottom">3 (10.0)<hr/></td><td align="center" valign="bottom">11 (36.7)<hr/></td><td align="center" valign="bottom">16 (53.3)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Moderate</italic></bold><hr/></td><td align="center" valign="bottom">26 (35.1)<hr/></td><td align="center" valign="bottom">27 (36.5)<hr/></td><td align="center" valign="bottom">21 (28.4)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Severe</italic></bold><hr/></td><td align="center" valign="bottom">14 (45.2)<hr/></td><td align="center" valign="bottom">8 (25.8)<hr/></td><td align="center" valign="bottom">9 (29.0)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Education - n (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>No formal</italic></bold><hr/></td><td align="center" valign="bottom">4 (50)<hr/></td><td align="center" valign="bottom">3 (37.5)<hr/></td><td align="center" valign="bottom">1 (12.5)<hr/></td><td align="center" valign="bottom">X2(10)&#x02009;=&#x02009;5.67, p&#x02009;=&#x02009;0.85<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>GSCE/O</italic></bold><hr/></td><td align="center" valign="bottom">12 (34.3)<hr/></td><td align="center" valign="bottom">9 (25.7)<hr/></td><td align="center" valign="bottom">14 (40)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>A level</italic></bold><hr/></td><td align="center" valign="bottom">10 (29.4)<hr/></td><td align="center" valign="bottom">12 (35.3)<hr/></td><td align="center" valign="bottom">12 (35.3)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Degree</italic></bold><hr/></td><td align="center" valign="bottom">8 (25.8)<hr/></td><td align="center" valign="bottom">11 (35.5)<hr/></td><td align="center" valign="bottom">12 (38.7)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;<bold><italic>Postgraduate</italic></bold><hr/></td><td align="center" valign="bottom">6 (40.0)<hr/></td><td align="center" valign="bottom">5 (33.3)<hr/></td><td align="center" valign="bottom">4 (26.7)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">&#x02003;&#x000a0;<bold><italic>Other</italic></bold></td><td align="center">3 (25.0)</td><td align="center">6 (50.0)</td><td align="center">3 (25)</td><td align="left">&#x000a0;</td></tr></tbody></table></table-wrap><p>The mean age of participants was 44&#x000a0;years, 78% were women. The mean length of symptoms reported was 10.8&#x000a0;years (SD&#x02009;=&#x02009;8.7). Mean IBS-SSS score at baseline was 241.9 (SD&#x02009;=&#x02009;87.7), which represents a moderate severity of IBS. Baseline characteristics were similar across the groups (please see Tables&#x000a0;<xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>), with the exception of Gender (X<sup>2</sup> p&#x02009;=&#x02009;0.034) and Deprivation scores (KW p&#x02009;=&#x02009;0.026) in the website conditions and IBS-SSS total mean (Fp&#x02009;=&#x02009;0.034) (also reflected in the symptom severity classification (p&#x02009;=&#x02009;0.021)) in the drug conditions. We assessed these variables in the ANCOVA/regression analyses. However, none were significant, so they were not included in the models.</p></sec><sec><title>Primary outcomes</title><p>The mean of the IBS-SSS score of the whole sample decreased (positive change) 52 points from baseline to the 6&#x000a0;week point and 35 points from baseline to the 12&#x000a0;week point. The mean of the IBS-QOL score of the sample increased (positive change) 6 points from baseline to the 6&#x000a0;week point and 5 points from baseline to the 12&#x000a0;week point (Figures&#x000a0;<xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>IBS symptom severity score at baseline, six and twelve weeks by website group.</p></caption><graphic xlink:href="1471-230X-13-68-2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>IBS symptom severity score at baseline, six and twelve weeks by medicine group.</p></caption><graphic xlink:href="1471-230X-13-68-3"/></fig><p>At 6&#x000a0;weeks there was no significant difference in IBS SSS or IBS-QOL between the medicine groups or for IBS-QOL for the website groups (see Tables&#x000a0;<xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>). However, there was a statistically significant difference seen in the IBS SSS for the website, with the no website group having a lower IBS SSS score than the website groups (IBS SSS no website =162.8 (95% CI 137.4-188.3), website 197.0 (172.4 - 221.7), Website + telephone support 208.0 (183.1-233.0) p&#x02009;=&#x02009;0.037). This difference disappeared by 12&#x000a0;weeks (see Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref> and Tables&#x000a0;<xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Main and secondary outcomes for website groups at six week follow up</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Website</bold></th><th align="center"><bold>Website + </bold><bold>support</bold></th><th align="center"><bold>No website group</bold></th><th align="center"><bold>Significance</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><italic>IBS-SSS total mean (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">197.0 (172.4 - 221.7)<hr/></td><td align="center" valign="bottom">208.0 (188.1 - 233.0)<hr/></td><td align="center" valign="bottom">162.8 (137.4 -188.3)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.037*<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-QOL score (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">71.6 (67.9-75.2)<hr/></td><td align="center" valign="bottom">67.6 (63.9-71.3)<hr/></td><td align="center" valign="bottom">69.4 (65.7-73.1)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.315<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for anxiety (n&#x02009;=&#x02009;114)</italic></bold><hr/></td><td align="center" valign="bottom">8.9 (7.9-9.8)<hr/></td><td align="center" valign="bottom">9.7 (8.8-10.6)<hr/></td><td align="center" valign="bottom">8.3 (7.3-9.2)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.109<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for depression (n&#x02009;=&#x02009;114) (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.122<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Normal (0&#x02013;7)</italic><hr/></td><td align="center" valign="bottom">35 (89.7)<hr/></td><td align="center" valign="bottom">28 (71.8)<hr/></td><td align="center" valign="bottom">31 (79.5)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Mild (8&#x02013;10)</italic><hr/></td><td align="center" valign="bottom">2 (5.1)<hr/></td><td align="center" valign="bottom">8 (20.5)<hr/></td><td align="center" valign="bottom">8 (20.5)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Moderate or Severe (11&#x02013;21)</italic><hr/></td><td align="center" valign="bottom">2 (5.1)<hr/></td><td align="center" valign="bottom">3 (7.7)<hr/></td><td align="center" valign="bottom">0 (0)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Enablement score (n&#x02009;=&#x02009;113) (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.000**<hr/></td></tr><tr><td align="left" valign="bottom"><italic>0</italic><hr/></td><td align="center" valign="bottom">7 (18.4)<hr/></td><td align="center" valign="bottom">4 (10.5)<hr/></td><td align="center" valign="bottom">21 (56.8)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>1-2</italic><hr/></td><td align="center" valign="bottom">7 (18.4)<hr/></td><td align="center" valign="bottom">5 (13.2)<hr/></td><td align="center" valign="bottom">4 (10.8)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>3-5</italic><hr/></td><td align="center" valign="bottom">13 (34.2)<hr/></td><td align="center" valign="bottom">15 (39.5)<hr/></td><td align="center" valign="bottom">7 (18.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left"><italic>6-12</italic></td><td align="center">11 (28.9)</td><td align="center">14 (36.8)</td><td align="center">5 (13.5)</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>Analysis of the 6&#x000a0;week follow-up scores.</p><p>ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression and Enablement (n (%).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Main and secondary outcomes for medicine groups at six week follow up</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Mebeverine</bold></th><th align="center"><bold>Methylcellulose</bold></th><th align="center"><bold>Placebo</bold></th><th align="center"><bold>Significance</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><italic>IBS-SSS total mean (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">183.3 (156.9-209.7)<hr/></td><td align="center" valign="bottom">174.0 (149.7-198.4)<hr/></td><td align="center" valign="bottom">210.6 (185.6-235.5)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.106<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-QOL score (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">69.5 (65.7-73.4)<hr/></td><td align="center" valign="bottom">69.4 (65.8-73.0)<hr/></td><td align="center" valign="bottom">69.7 (66.0-73.3)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.994<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for anxiety (n&#x02009;=&#x02009;114)</italic></bold><hr/></td><td align="center" valign="bottom">8.7 (7.7-9.7)<hr/></td><td align="center" valign="bottom">9.0 (8.1-9.9)<hr/></td><td align="center" valign="bottom">9.2 (8.3-10.1)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.743<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for depression (n&#x02009;=&#x02009;114) (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.590<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Normal (0&#x02013;7)</italic><hr/></td><td align="center" valign="bottom">29 (30.9)<hr/></td><td align="center" valign="bottom">36 (38.3)<hr/></td><td align="center" valign="bottom">29 (30.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Mild (8&#x02013;10)</italic><hr/></td><td align="center" valign="bottom">3 (16.7)<hr/></td><td align="center" valign="bottom">5 (27.8)<hr/></td><td align="center" valign="bottom">10 (55.6)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Moderate or Severe (11&#x02013;21)</italic><hr/></td><td align="center" valign="bottom">2 (40.0)<hr/></td><td align="center" valign="bottom">0 (0)<hr/></td><td align="center" valign="bottom">3 (60.0)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Enablement score (n&#x02009;=&#x02009;113)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.563<hr/></td></tr><tr><td align="left" valign="bottom"><italic>0</italic><hr/></td><td align="center" valign="bottom">6 (19.4)<hr/></td><td align="center" valign="bottom">14 (35.9)<hr/></td><td align="center" valign="bottom">12 (27.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>1-2</italic><hr/></td><td align="center" valign="bottom">5 (16.1)<hr/></td><td align="center" valign="bottom">6 (15.4)<hr/></td><td align="center" valign="bottom">5 (11.6)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>3-5</italic><hr/></td><td align="center" valign="bottom">9 (29.0)<hr/></td><td align="center" valign="bottom">11 (28.2)<hr/></td><td align="center" valign="bottom">15 (34.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left"><italic>6-12</italic></td><td align="center">11 (35.5)</td><td align="center">8 (20.5)</td><td align="center">11 (25.6)</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>Analysis of the 6&#x000a0;week follow-up scores.</p><p>ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression and Enablement (n (%).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Main and secondary outcomes for website groups at twelve week follow up</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Website</bold></th><th align="center"><bold>Website</bold> + <bold>support</bold></th><th align="center"><bold>No website group</bold></th><th align="center"><bold>Significance</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><italic>IBS-SSS total mean (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">207.9 (187.6 &#x02013; 228.1)<hr/></td><td align="center" valign="bottom">193.4 (173.0- 213.8)<hr/></td><td align="center" valign="bottom">218.2 (197.4-238.9)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.243<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-QOL score (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">71.6 (67.2 - 76.1)<hr/></td><td align="center" valign="bottom">69.5 (65.0 - 74.0)<hr/></td><td align="center" valign="bottom">64.3 (59.8 &#x02013; 68.9)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.068<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for anxiety (n&#x02009;=&#x02009;114)</italic></bold><hr/></td><td align="center" valign="bottom">8.8 (8.0- 9.7)<hr/></td><td align="center" valign="bottom">9.2 (8.3 -10.0)<hr/></td><td align="center" valign="bottom">8.0 (7.1 -8.8)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.123<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for depression (n&#x02009;=&#x02009;114) (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.981<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Normal (0&#x02013;7)</italic><hr/></td><td align="center" valign="bottom">32 (84.2)<hr/></td><td align="center" valign="bottom">31 (79.5)<hr/></td><td align="center" valign="bottom">30 (81.1)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Mild (8&#x02013;10)</italic><hr/></td><td align="center" valign="bottom">6 (15.8)<hr/></td><td align="center" valign="bottom">4 (10.3)<hr/></td><td align="center" valign="bottom">4 (10.8)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Moderate or Severe (11&#x02013;21)</italic><hr/></td><td align="center" valign="bottom">0 (0)<hr/></td><td align="center" valign="bottom">4 (10.3)<hr/></td><td align="center" valign="bottom">3 (8.1)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Enablement score (n&#x02009;=&#x02009;113) (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.000**<hr/></td></tr><tr><td align="left" valign="bottom"><italic>0</italic><hr/></td><td align="center" valign="bottom">7 (18.4)<hr/></td><td align="center" valign="bottom">4 (10.5)<hr/></td><td align="center" valign="bottom">21 (56.8)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>1-2</italic><hr/></td><td align="center" valign="bottom">7 (18.4)<hr/></td><td align="center" valign="bottom">5 (13.2)<hr/></td><td align="center" valign="bottom">4 (10.8)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>3-5</italic><hr/></td><td align="center" valign="bottom">13 (34.2)<hr/></td><td align="center" valign="bottom">15 (39.5)<hr/></td><td align="center" valign="bottom">7 (18.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>6-12</italic><hr/></td><td align="center" valign="bottom">11 (28.9)<hr/></td><td align="center" valign="bottom">14 (36.8)<hr/></td><td align="center" valign="bottom">5 (13.5)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>SGA (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Responders</italic><hr/></td><td align="center" valign="bottom">16 (45.7)<hr/></td><td align="center" valign="bottom">24 (63.2)<hr/></td><td align="center" valign="bottom">12 (32.4)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.035*<hr/></td></tr><tr><td align="left"><italic>Non responders</italic></td><td align="center">19 (54.3)</td><td align="center">14 (36.8)</td><td align="center">25 (67.6)</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>Analysis of the 12&#x000a0;week follow-up scores.</p><p>ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression, Enablement and SGA (n (%).</p></table-wrap-foot></table-wrap><p>No significant difference was found between the self-management website groups or the medicine groups for the IBS SSS or quality of life at the twelve week follow up. (see Tables&#x000a0;<xref ref-type="table" rid="T6">6</xref> and <xref ref-type="table" rid="T7">7</xref> for summary statistics).</p><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Main and secondary outcomes for medicine groups at twelve week follow up</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Mebeverine</bold></th><th align="center"><bold>Methylcellulose</bold></th><th align="center"><bold>Placebo</bold></th><th align="center"><bold>Significance</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><italic>IBS-SSS total mean (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">203.1(181.3- 223.0)<hr/></td><td align="center" valign="bottom">205.4 (185.3 -225.5)<hr/></td><td align="center" valign="bottom">210.9 (191.1 - 230.7)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.865<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>IBS-QOL score (n&#x02009;=&#x02009;123)</italic></bold><hr/></td><td align="center" valign="bottom">68.9 (64.1 &#x02013; 73.6)<hr/></td><td align="center" valign="bottom">66.3 (61.9 &#x02013; 70.8)<hr/></td><td align="center" valign="bottom">70.2 (65.9 &#x02013; 74.6)<hr/></td><td align="center" valign="bottom">P&#x02009;=&#x02009;0.453<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for anxiety (n&#x02009;=&#x02009;114)</italic></bold><hr/></td><td align="center" valign="bottom">8.2 (7.3 &#x02013; 9.1)<hr/></td><td align="center" valign="bottom">8.7 (7.9- 9.6)<hr/></td><td align="center" valign="bottom">9.0 (8.2 -9.8)<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.422<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>HADS score for depression (n&#x02009;=&#x02009;114) (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">P&#x02009;=&#x02009;0.655<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Normal (0&#x02013;7)</italic><hr/></td><td align="center" valign="bottom">25 (78.1)<hr/></td><td align="center" valign="bottom">35 (89.7)<hr/></td><td align="center" valign="bottom">33 (76.7)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Mild (8&#x02013;10)</italic><hr/></td><td align="center" valign="bottom">5 (15.6)<hr/></td><td align="center" valign="bottom">2 (5.1)<hr/></td><td align="center" valign="bottom">7 (16.3)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>Moderate or Severe (11&#x02013;21)</italic><hr/></td><td align="center" valign="bottom">2 (6.3)<hr/></td><td align="center" valign="bottom">2 (5.1)<hr/></td><td align="center" valign="bottom">3 (7.0)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Enablement score (n&#x02009;=&#x02009;113)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">P&#x02009;=&#x02009;0.231<hr/></td></tr><tr><td align="left" valign="bottom"><italic>0</italic><hr/></td><td align="center" valign="bottom">6 (19.4)<hr/></td><td align="center" valign="bottom">14 (35.9)<hr/></td><td align="center" valign="bottom">12 (27.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>1-2</italic><hr/></td><td align="center" valign="bottom">5 (16.1)<hr/></td><td align="center" valign="bottom">6 (15.4)<hr/></td><td align="center" valign="bottom">5 (11.6)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>3-5</italic><hr/></td><td align="center" valign="bottom">9 (29.0)<hr/></td><td align="center" valign="bottom">11 (28.2)<hr/></td><td align="center" valign="bottom">15 (34.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><italic>6-12</italic><hr/></td><td align="center" valign="bottom">11 (35.5)<hr/></td><td align="center" valign="bottom">8 (20.5)<hr/></td><td align="center" valign="bottom">11(25.6)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>SGA (%)</italic></bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold><italic>Responders</italic></bold><hr/></td><td align="center" valign="bottom">16 (57.1)<hr/></td><td align="center" valign="bottom">17 (43.6)<hr/></td><td align="center" valign="bottom">19 (44.2)<hr/></td><td align="center" valign="bottom">P&#x02009;=&#x02009;0.538<hr/></td></tr><tr><td align="left"><bold><italic>Non responders</italic></bold></td><td align="center">12 (42.9)</td><td align="center">22 (56.4)</td><td align="center">24 (55.8)</td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression, Enablement and SGA (n (%).</p></table-wrap-foot></table-wrap><p>There was no evidence of interactions between the medicine and website groups in any of the analyses.</p><p>The mean scores suggest improvements across all groups particularly at the 6&#x000a0;week (end of treatment) period (Tables&#x000a0;<xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>). There was however a trend for continued improvement in the self-management groups (particularly those who had the telephone support) whilst those in the no website group and the medication groups appeared to lose some of these gains at 12&#x000a0;weeks (see Figures&#x000a0;<xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref> and Tables&#x000a0;<xref ref-type="table" rid="T6">6</xref> and <xref ref-type="table" rid="T7">7</xref>).</p></sec><sec><title>Secondary outcomes</title><p>No significant difference was found in HADs, Enablement or SGA between the medication groups or in the HADs scores between the website groups (Tables&#x000a0;<xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T7">7</xref>). A highly significant difference was found in the Enablement scores at 6 and 12&#x000a0;week follow-up between the website conditions and the control group (Tables&#x000a0;<xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T6">6</xref>). The participants in the Website groups reported better Enablement than the ones in the no website group. The higher scores were found in the Website plus support condition. This suggests that the participants who had access to the website coped better with their IBS symptoms than the control group.</p><p>A significant difference was also found in the SGA at 12&#x000a0;week follow-up between the website groups (Table&#x000a0;<xref ref-type="table" rid="T6">6</xref>). The participants in the website groups had better scores than the no website group, indicating that the participants who had access to the website rated their overall IBS symptom relief as significantly better than the individuals who had no access to the website.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Summary of main findings</title><p>The trial has demonstrated that it is feasible to recruit and randomise patients with IBS from many GP practices to a complex trial and achieve high follow-up rates.</p><p>The results must be interpreted with caution as this is an exploratory study with relatively low numbers and power. No statistically significant differences were seen between the medication groups for the main outcome measures (IBS SSS and IBS-QOL) at 6 or 12&#x000a0;weeks. Nor were there any statistically significant differences between the website groups for the IBS-QOL at 6 or 12&#x000a0;weeks or IBS SSS at 12&#x000a0;weeks. However, there was a statistically significant difference seen in the IBS SSS for the website at 6&#x000a0;weeks, with the &#x02018;no website&#x02019; group having a lower IBS SSS score than the website groups, but this difference disappeared by 12&#x000a0;weeks.</p><p>There were no differences in the secondary outcomes in the medicine groups.</p><p>In the website groups, there was significantly increased Enablement at 6 and 12&#x000a0;weeks and a significantly more participants scored Subjective Assessment of Global relief (SGA) as improved at 12&#x000a0;weeks compared to the No Website group.</p></sec><sec><title>Strengths and limitations</title><p>This exploratory trial was the first to look at providing CBT as a web-based self-management programme for patients with IBS. The factorial design allowed the feasibility of undertaking a trial to assess the effectiveness of common IBS medications to be explored at the same time.</p><p>Participants were asked to take 7 large over-encapsulated tablets a day for 6&#x000a0;weeks. Despite this, compliance with the medication taking was good.</p><p>The lack of difference between the medication groups may be due to low power with the limited numbers in this trial. A larger trial will be able to provide more definitive results. Ideally, smaller trial medication would be sourced for a larger trial to further improve compliance and reduce the placebo effect of taking the tablets.</p><p>Expectancy effects (i.e. people's expectancy of web treatment and drug treatment) and the placebo effect may have influenced the trial results. We did not measure treatment expectancy effects in this study.</p><p>Over 5700 patients were invited by their GP to participate in this study with 135 being randomised. Thus a small subset of the patients recorded as having IBS by their GPs entered the study. This low recruitment rate is not unexpected in a study requiring patients to be on no initial medication, to take many large tablets a day and participate in a self-management programme for 6&#x000a0;weeks, but it may reflect a more committed group of participants and affect the generalisability of the study findings. Reasons for declining to enter the study have been sought and recorded and the study sample is similar in gender and age to the invited participants.</p></sec><sec><title>Comparisons with other studies</title><p>There are a limited number of published trials of CBT for IBS but they indicate a positive effect for CBT on IBS over a range of outcome measures [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B30">30</xref>] in the short-term (up to 3&#x000a0;months). However, information is lacking for longer term follow up. For instance, a trial of face to face CBT plus mebeverine (6 &#x000d7; 50&#x000a0;minute CBT sessions over 6&#x000a0;week delivered by general practice nurses) against mebeverine alone in a primary care setting in London [<xref ref-type="bibr" rid="B8">8</xref>] showed a significant reduction in IBS-SSS in the CBT arm at 3&#x000a0;months but not at 12&#x000a0;months follow up.</p><p>The lack of improvement in the IBS SSS and IBS-QOL in the website self-management groups in this study is disappointing as the paper-based self-management programme from which the Regul8 website was developed [<xref ref-type="bibr" rid="B20">20</xref>] did show a significant improvement in IBS SSS scores in the self-management group compared to the control group. It may be that an effect of the website was masked by the general improvement in all groups during the length of the trial. It is acknowledged in many trials that IBS symptoms have a large placebo response to any intervention and this can make it difficult to distinguish true treatment effects, particularly in a small study. However, we found a trend for continued improvement in the self-management group (particularly those who had the telephone support) whilst those in the No Website group and the medication groups appeared to lose some of these gains at 12&#x000a0;weeks (see Figures&#x000a0;<xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>). Longer term follow up may reveal differences between the website groups. Two other reasons why the Regul8 programme may be less successful than the paper-based manual are that: the earlier study used an experienced therapist, and had significantly more therapist contact time. In this study a nurse with only minimal CBT training delivered the intervention. In addition, of those that had access to the Regul8 programme, half had no therapist support at all and half had one, 30&#x000a0;min telephone support session, whereas in the trial of the paper-based manual, one face to face and two telephone support sessions were offered to participants (3&#x000a0;hours in total). Therapist support is expensive compared to a stand-alone website and thus was deliberately kept to a minimum for this trial. However, recently published trials of internet interventions for IBS [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B30">30</xref>] and qualitative data from this study suggest that it is important to assist engagement with the website.</p><p>The finding that Enablement scores were higher in those that had access to the Regul8 programme suggests that these participants felt better able to cope with their symptoms. Additionally, those that received the telephone session had higher Enablement than those with access to the website without support. This suggests benefit from the website which is enhanced by therapist support and strengthens the postulation that the amount of support offered in this study may have been insufficient. Ability to cope with IBS symptoms and continue a full life is clearly an important outcome irrespective of symptom severity. Improvements in the Work and Social Adjustment Scale, a measure of the ability to continue work and other activities with IBS, was shown to be improved by CBT in the long term (12&#x000a0;month follow up) in the Kennedy trial [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The lack of any significant effect on IBS outcomes in the medication arms of this study, may be due to limited power, and would need to be confirmed in a larger trial but are not unsurprising as a Cochrane review [<xref ref-type="bibr" rid="B6">6</xref>] has highlighted the poor evidence of their effectiveness.</p></sec><sec><title>Implications for future research and clinical practice</title><p>The factorial trial design for this study had the benefit of providing data for both the medication and the website groups but this may have limited the ability of the trial to show an effect for the CBT self-management programme, since the key to self-management is being able to attribute symptom improvement to cognitive and behavioural changes. In a blinded trial participants would have had some difficulty knowing whether any change in their symptoms was due to the medication they were taking or to the CBT self-management principles they were trying to employ. This issue was raised in discussion with patients in the qualitative interviews. The effect of including medication the factorial design, may have been to reduce their confidence in employing the CBT techniques. Thus a definitive trial of the website should probably not include a blinded medication component.</p><p>When recruiting participants from primary care for this trial, it was found to be important to screen potential participants with the ROME III and exclusion criteria as 98 of the 265 potential participants who completed the screening questionnaire either did not fulfil the ROME criteria or met exclusion criteria.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>This study demonstrates that a trial of this type is feasible in primary care and can be successfully completed with robust trial procedures and high levels of follow up. A larger trial (or trials) would have the power to determine more definitive outcomes. Undertaking separate medicine and website self-management programme trials is likely to be appropriate in the larger trials. Increasing the therapist support sessions for the web-based self-management programme would seem logical approach to try to further increase patient enablement, which is an important aspect of self-managing a chronic condition such as IBS.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>HE, RMM, PL and LY were involved in the conception and design of the study and applied for funding. HE wrote the first draft of the grant application, is Lead investigator and Principal Investigator. RMM oversaw the adaptation of the paper-based CBT manual into the website, the development of the telephone protocol, and nurse training and supervision. LT and AS developed the website and managed the trial. LY oversaw the website programming package. NC (Consultant Gastroenterologist) was a clinical expert advisor. PS developed the Statistical Plan and Randomisation. All Authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-230X/13/68/prepub">http://www.biomedcentral.com/1471-230X/13/68/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>This study was funded by a grant from the Research for Patient Benefit (RfPB) funding stream, from the National Institute of Health Research (NIHR), UK. This paper outlines independent research commissioned by the National Institute for Health Research (NIHR). The views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.</p><p>The web-based materials used for this study were created using the LifeGuide system developed as part of the national Digital Social Science programme funded by the UK Economic and Social Research Council, in collaboration with the LifeGuide team.</p><p>Thank you to the Research Nurses: Carol Bowerman and Carolyn Powell whose hard work enabled the successful recruitment and follow up of participants.</p><p>Thank you also to the independent members of the Trial Steering Committee, Chris Salisbury and Colin Greaves, to the Patients who participated in the Think Aloud Interviews, sat on the Trial Management Committee and who participated in the trial.</p><p>This study was funded by a grant from the Research for Patient Benefit (RfPB) funding stream, from the National Institute of Health Research (NIHR), UK. Grant Number: PB-PG-0807-13081.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><collab>British Society of Gastroenterology</collab><article-title>Care of patients with gastrointestinal disorders in the United Kingdom: a strategy for the future</article-title><source>Gut</source><year>2007</year><volume>13</volume><fpage>1</fpage><lpage>56</lpage></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Akehurst</surname><given-names>R</given-names></name><name><surname>Kaltenthaler</surname><given-names>E</given-names></name><article-title>Treatment of irritable bowel syndrome: a review of randomised controlled trials</article-title><source>Gut</source><year>2001</year><volume>13</volume><issue>2</issue><fpage>272</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1136/gut.48.2.272</pub-id><pub-id pub-id-type="pmid">11156653</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Aziz</surname><given-names>Q</given-names></name><name><surname>Creed</surname><given-names>F</given-names></name><name><surname>Emmanuel</surname><given-names>A</given-names></name><name><surname>Houghton</surname><given-names>L</given-names></name><name><surname>Hungin</surname><given-names>P</given-names></name><article-title>Guidelines for the management of Irritable Bowel Syndrome</article-title><source>Gut</source><year>2007</year><volume>13</volume><issue>12</issue><fpage>1770</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1136/gut.2007.119446. 8-5-2007</pub-id><pub-id pub-id-type="pmid">17488783</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Prior</surname><given-names>A</given-names></name><name><surname>Whorwell</surname><given-names>PJ</given-names></name><article-title>Double blind study of ispaghula in irritable bowel syndrome</article-title><source>Gut</source><year>1987</year><volume>13</volume><issue>11</issue><fpage>1510</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1136/gut.28.11.1510</pub-id><pub-id pub-id-type="pmid">3322956</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="book"><collab>NICE</collab><source>Irritable bowel syndrome in adults</source><year>2008</year><publisher-name>NICE</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://guidance.nice.org.uk/CG61">http://guidance.nice.org.uk/CG61</ext-link></comment></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Ruepert</surname><given-names>L</given-names></name><name><surname>Quartero</surname><given-names>AO</given-names></name><name><surname>de Wit</surname><given-names>NJ</given-names></name><name><surname>van der Heijden</surname><given-names>GJ</given-names></name><name><surname>Rubin</surname><given-names>G</given-names></name><name><surname>Muris</surname><given-names>JWM</given-names></name><article-title>Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome</article-title><source>Cochrane Database of Systematic Reviews</source><year>2011</year><volume>13</volume><fpage>&#x02009;</fpage><comment>Issue 8. Art. No.: CD003460. DOI: 10.1002/14651858.CD003460.pub3</comment></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Hayee</surname><given-names>B</given-names></name><name><surname>Forgacs</surname><given-names>I</given-names></name><article-title>Clinical review: psychological approach to managing irritable bowel syndrome</article-title><source>BMJ</source><year>2007</year><volume>13</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1136/bmj.39199.679236.AE</pub-id><pub-id pub-id-type="pmid">17525453</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kennedy</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Darnley</surname><given-names>S</given-names></name><name><surname>Seed</surname><given-names>P</given-names></name><name><surname>Wessely</surname><given-names>S</given-names></name><name><surname>Chalder</surname><given-names>T</given-names></name><article-title>Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial</article-title><source>BMJ</source><year>2005</year><volume>13</volume><issue>7514</issue><fpage>435</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1136/bmj.38545.505764.06</pub-id><pub-id pub-id-type="pmid">16093252</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="other"><name><surname>Zijdenbos</surname><given-names>IL</given-names></name><name><surname>de Wit</surname><given-names>NJ</given-names></name><name><surname>van der Heijden</surname><given-names>GJ</given-names></name><name><surname>Rubin</surname><given-names>G</given-names></name><name><surname>Quartero</surname><given-names>AO</given-names></name><article-title>Psychological treatments for the management of irritable bowel syndrome</article-title><source>Cochrane Database of Systematic Reviews</source><year>2009</year><comment>Issue 1. Art. No.: CD006442. DOI: 10.1002/14651858.CD006442.pub2</comment></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Lackner</surname><given-names>JM</given-names></name><name><surname>Jaccard</surname><given-names>J</given-names></name><name><surname>Krasner</surname><given-names>SS</given-names></name><name><surname>Katz</surname><given-names>LA</given-names></name><name><surname>Gudleski</surname><given-names>GD</given-names></name><name><surname>Holroyd</surname><given-names>K</given-names></name><article-title>Self administered cognitive behavior therapy for moderate to severe IBS: clinical efficacy, tolerability, feasibility</article-title><source>Clin Gastroenterol Hepatol</source><year>2008</year><volume>13</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2008.03.004</pub-id><pub-id pub-id-type="pmid">18524691</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Toner</surname><given-names>BB</given-names></name><name><surname>Whitehead</surname><given-names>WE</given-names></name><name><surname>Diamant</surname><given-names>NE</given-names></name><name><surname>Dalton</surname><given-names>CB</given-names></name><name><surname>Duncan</surname><given-names>S</given-names></name><article-title>Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders</article-title><source>Gastroenterol</source><year>2003</year><volume>13</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(03)00669-3</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>McCrone</surname><given-names>P</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>T</given-names></name><name><surname>Seed</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Darnley</surname><given-names>S</given-names></name><article-title>Cost effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome</article-title><source>Eur J Gastroenterol Hepatol</source><year>2008</year><volume>13</volume><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e3282f2519d</pub-id><pub-id pub-id-type="pmid">18334867</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>G</given-names></name><name><surname>Bergstrom</surname><given-names>J</given-names></name><name><surname>Hollandare</surname><given-names>F</given-names></name><name><surname>Carlbring</surname><given-names>P</given-names></name><name><surname>Kaldo</surname><given-names>V</given-names></name><name><surname>Ekselius</surname><given-names>L</given-names></name><article-title>Internet-based self-help for depression: randomised controlled trial</article-title><source>BJ Psychiatry</source><year>2005</year><volume>13</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1192/bjp.187.5.456</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>G</given-names></name><name><surname>Stromgren</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>L</given-names></name><name><surname>Lyttkens</surname><given-names>L</given-names></name><article-title>Randomised controlled trail of internet-based cognitive behavioural therapy for distress associated with tinnitus</article-title><source>Psychosom Med</source><year>2002</year><volume>13</volume><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1097/01.PSY.0000031577.42041.F8</pub-id><pub-id pub-id-type="pmid">12271112</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Espie</surname><given-names>CA</given-names></name><name><surname>Kyle</surname><given-names>SD</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Ong</surname><given-names>JC</given-names></name><name><surname>Douglas</surname><given-names>NJ</given-names></name><name><surname>Hames</surname><given-names>P</given-names></name><article-title>A randomised placebo-controlled trial of onlibe cognitive behavioural therapy for chronic insomnia disorder delivered via an automated media-rich web application</article-title><source>Sleep</source><year>2012</year><volume>13</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">22654196</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="book"><collab>NICE</collab><source>Depression and Anxiety - Computerised Cognitive Behavioural Therapy (CCBT), TA97</source><year>2006</year><publisher-name>NICE</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://guidance.nice.org.uk/TA97">http://guidance.nice.org.uk/TA97</ext-link></comment></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Ljotsson</surname><given-names>B</given-names></name><name><surname>Hedman</surname><given-names>E</given-names></name><name><surname>Lindfors</surname><given-names>P</given-names></name><name><surname>Hursti</surname><given-names>T</given-names></name><name><surname>Lindefors</surname><given-names>N</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name><article-title>Long-term follow-up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome</article-title><source>Behav Res Ther</source><year>2011</year><volume>13</volume><fpage>5861</fpage></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Hunt</surname><given-names>MG</given-names></name><name><surname>Moshier</surname><given-names>S</given-names></name><name><surname>Milonova</surname><given-names>M</given-names></name><article-title>Brief cognitive-behavioral internet therapy for irritable bowel syndrome</article-title><source>Behav Res Ther</source><year>2009</year><volume>13</volume><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.brat.2009.05.002</pub-id><pub-id pub-id-type="pmid">19570525</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Everitt</surname><given-names>H</given-names></name><name><surname>Moss-Morris</surname><given-names>R</given-names></name><name><surname>Sibelli</surname><given-names>A</given-names></name><name><surname>Tapp</surname><given-names>L</given-names></name><name><surname>Coleman</surname><given-names>N</given-names></name><name><surname>Yardley</surname><given-names>L</given-names></name><article-title>Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS Trial)</article-title><source>BMC Gastroenterol</source><year>2010</year><volume>13</volume><fpage>136</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-10-136</pub-id><pub-id pub-id-type="pmid">21087463</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Moss-Morris</surname><given-names>R</given-names></name><name><surname>McAlpine</surname><given-names>L</given-names></name><name><surname>Didsbury</surname><given-names>LP</given-names></name><name><surname>Spence</surname><given-names>MJ</given-names></name><article-title>A randomised controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care</article-title><source>Psychol Med</source><year>2010</year><volume>13</volume><fpage>94</fpage></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Lucy</surname><given-names>Y</given-names></name><name><surname>Morrison</surname><given-names>LG</given-names></name><name><surname>Panayiota</surname><given-names>A</given-names></name><name><surname>Judith</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>L</given-names></name><article-title>Understanding reactions to an internet-delivered health-care intervention: accommodating user preferences for information provision</article-title><source>BMC Medical Informatics and Decision Making</source><year>2010</year><volume>13</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1186/1472-6947-10-52</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Cotton</surname><given-names>D</given-names></name><name><surname>Gresty</surname><given-names>K</given-names></name><article-title>Reflecting on the think-aloud method for evaluating e learning</article-title><source>Br J Educ Technol</source><year>2006</year><volume>13</volume><issue>1</issue><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/j.1467-8535.2005.00521.x</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Yardley</surname><given-names>L</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Michie</surname><given-names>S</given-names></name><name><surname>Weal</surname><given-names>M</given-names></name><name><surname>Wills</surname><given-names>G</given-names></name><name><surname>Little</surname><given-names>P</given-names></name><article-title>Evaluation of a web-based intervention providing tailored advice for self-management of minor respiratory symptoms: exploratory randomized controlled trial</article-title><source>J Med Internet Res</source><year>2010</year><volume>13</volume><fpage>e66</fpage><pub-id pub-id-type="doi">10.2196/jmir.1599</pub-id><pub-id pub-id-type="pmid">21159599</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Francis</surname><given-names>CY</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Whorwell</surname><given-names>PJ</given-names></name><article-title>The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress</article-title><source>Aliment Pharmacol Ther</source><year>1997</year><volume>13</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1997.142318000.x</pub-id><pub-id pub-id-type="pmid">9146781</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Frederick</surname><given-names>IO</given-names></name><article-title>Quality of life in persons with irritable bowel syndrome. Development and validation of a new measure</article-title><source>Dig Dis Sci</source><year>1998</year><volume>13</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1023/A:1018831127942</pub-id><pub-id pub-id-type="pmid">9512138</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Whitehead</surname><given-names>WE</given-names></name><name><surname>Toner</surname><given-names>BB</given-names></name><name><surname>Diamant</surname><given-names>NE</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><article-title>Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>13</volume><issue>4</issue><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">10763950</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Howie</surname><given-names>JGR</given-names></name><name><surname>Heaney</surname><given-names>DJ</given-names></name><name><surname>Maxwell</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>JJ</given-names></name><article-title>A comparison of a Patient Enablement Instrument (PEI) against two established satisfaction scales as an outcome measure of primary care consultations</article-title><source>Fam Pract</source><year>1998</year><volume>13</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1093/fampra/15.2.165</pub-id><pub-id pub-id-type="pmid">9613486</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Muller-Lissner</surname><given-names>S</given-names></name><name><surname>Koch</surname><given-names>G</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Drossman</surname><given-names>D</given-names></name><name><surname>Rueegg</surname><given-names>P</given-names></name><name><surname>Dunger-Baldauf</surname><given-names>C</given-names></name><article-title>Subject's global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials</article-title><source>J Clin Epidemiol</source><year>2003</year><volume>13</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(03)00027-1</pub-id><pub-id pub-id-type="pmid">12767407</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatrica Scandinavia</source><year>1983</year><volume>13</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1983.tb09716.x</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Ljotsson</surname><given-names>B</given-names></name><name><surname>Falk</surname><given-names>L</given-names></name><name><surname>Vesterlund</surname><given-names>AW</given-names></name><name><surname>Hedman</surname><given-names>E</given-names></name><name><surname>Linfors</surname><given-names>P</given-names></name><name><surname>Ruck</surname><given-names>C</given-names></name><article-title>Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome&#x02013;a randomized controlled trial</article-title><source>Behav Res Ther</source><year>2010</year><volume>13</volume><fpage>531</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/j.brat.2010.03.003</pub-id><pub-id pub-id-type="pmid">20362976</pub-id></mixed-citation></ref></ref-list></back></article>